FDA accepts Bayer sNDA to expand KERENDIA for non-diabetic CKD
Bayer said the U.S. FDA accepted its supplemental New Drug Application for KERENDIA to treat adults with non-diabetic chronic kidney disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.